Ashvattha Therapeutics, Inc. — Form D/A
Ashvattha Therapeutics, Inc. of REDWOOD CITY, CA, a company, filed a Form D amendment with the SEC on 2022-12-30. $60.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-12-30
- Form: D/A
- Accession: 0001104659-22-131412
- Industry: Biotechnology
- Exemptions: 06b
- Amount sold: $60.2M
- Investors: 107
- Date of first sale: 2021-04-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-397980
Issuer
- Name: Ashvattha Therapeutics, Inc.
- CIK: 0001668528
- Entity type: Corporation
- Jurisdiction: CALIFORNIA
- Incorporated: 2015
- Address: 1235 RADIO ROAD, SUITE 200, REDWOOD CITY, CA, 94065
- Phone: (650) 868-5853
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| JEFFREY CLELAND | Director | BALTIMORE, MD |
| George Montgomery | Director | Redwood City, CA |
| Jay Zaveri | Director | Campbell, CA |
| Yuhang Zhao | Director | Redwood City, CA |
| JEFFREY CLELAND | Executive Officer | BALTIMORE, MD |
| Kannan Rangaramanujam | Director | Highland, MD |
| Kannan Rangaramanujam | Executive Officer | Highland, MD |
| Sujatha Kannan | Director | Highland, MD |
| Sujatha Kannan | Executive Officer | Highland, MD |
| Barbara Slusher | Director | Redwood City, CA |
| Justin Hanes | Executive Officer | Redwood City, CA |
Other filings by this issuer (6)
More